Molecular Docking of Fisetin as a Multi-target drug in the treatment of Alzheimer’s disease Malathi R*, Dsouza Vailina**, Puja***, Rithika R****, Sneha P***** Department of Life Sciences, Kristu Jayanti College, AutonomousK. Narayanapura, Kothanur, Bengaluru, Karnataka, 560077 *Corresponding Author E-mail: malathi@kristujayanti.com
**20ls701010@kristujayanti.com
***20ls701011@kristujayanti.com
****20ls701017@kristujayanti.com
*****20ls701016@kristujayanti.com
Online Published on 07 February, 2024. Abstract Alzheimer’s disease is a slow deadly form of dementia occurring in almost 70% of the older generation. Throughout the world, there are approximately 47 million people affected. Countries that are mostly affected by Alzheimer’s disease with the highest are Turkey and Lebanon by 57% and 56% respectively. The lowest rates include India, Cambodia, Georgia, and Singapore. This includes symptoms such as disorientation, mood swings, behavioral issues, etc. ultimately leading to death. The primitive appearance of the alpha-beta plaques and neurofibrillary tangles in the different regions of the brain leads to the cause of AD progression. In this present study, Fisetin which is a plant flavonoid having neurotropic and neuroprotective properties is docked with the drug targets of Alzheimer’s disease. The study was focused on analysing the molecular interaction of Fisetin with potential drug targets of Alzheimer’s disease. The docking was performed using AutoDock 4.2. The minimum binding energy studies explain the efficiency of the ligand binding with the therapeutic target proteins. Proteins play a significant role in Alzheimer’s disease as it is responsible for various functions which also are the major attributes of Alzheimer's disease namely amyloid-β production, tau phosphorylation, synaptic function, neurogenesis, and memory which all are influenced by dysregulation of this enzyme. Four proteins were selected based on the action and function they play in the progression of Alzheimer’s disease namely FYN tyrosine kinase, Beta Secretase (BACE 1), Gamma secretase, and Glycogen synthase kinase 3-beta (GSK3-β). The minimum binding energy scores for the following 3D molecular structures were FYN tyrosine kinase = -8.2 kcal/mol, BACE1= -10.67kcal/mol, Gamma secretase = - 10.03kcal/mol, GSK3 Beta = -10.47kcal/mol; No. of hydrogen bonds: 12, 10, 10 and 21 respectively. From the 4 potential Alzheimer’s drug targets, Glycogen synthase kinase 3-beta (GSK3-β) and Beta Secretase, had the best interaction with Fisetin with the lowest binding energy. Along with this Fisetin was analyzed for its molecular properties, drug-likeness, biological activity, and toxicity using the Way2drug bio tool. Top Keywords Fisetin, Docking, Therapeutic target proteins, AutoDock, β secretase, γ secretase, Fyn tyrosine kinase, Glycogen synthase kinase 3-beta (GSK3-β). Top |